La cadena de opciones muestra datos clave de las opciones de acciones de Meihua Intl Medical Techs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Meihua Intl Medical Techs..

Meihua Intl Medical Techs (NASDAQ:MHUA) Bolsa, Cadena de Opciones

Meihua Intl Medical Techs

Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

Meihua International Medical Technologies Co., Ltd. - Ordinary Shares

Meihua International Medical Technologies Co Ltd

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 8.06% on an annualized basis producing an average annual return of 20.52%. Currently, Molina Healthcare has a market capitalization of $14.91 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $16,670.36 today based on a price of $275.02 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751406310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 15 Years

<a href="https://www.wsj.com/business/media/warner-music-to-cut-jobs-as-part-of-effort-to-slash-costs-by-300-million-646c2269">https://www.wsj.com/business/media/warner-music-to-cut-jobs-as-part-of-effort-to-slash-costs-by-300-million-646c2269</a>

General

'Warner Music to Cut Jobs as Part of Effort to Slash Costs by $300 Million'- WSJ

IMAC Hldgs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BACK#OTC">BACK</a>) reported quarterly losses of $(1.08) per share. This is a 176.92 percent decrease over losses of $(0.39) per share from the same period last year. The company reported $1.500 thousand in sales this quarter.

Earnings

BACK

IMAC Hldgs Q1 EPS $(1.08) Down From $(0.39) YoY, Sales $1.500K

AMPY

Amplify Energy Enters Into A Definitive Agreement To Sell All Of Its Non-Operated Working Interest In Its Eagle Ford Assets To Murphy Exploration & Production Company For $23M

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has outperformed the market over the past 20 years by 29.81% on an annualized basis producing an average annual return of 38.28%. Currently, NVIDIA has a market capitalization of $3.73 trillion. 
Buying $1000 In NVDA: If an investor had bought $1000 of NVDA stock 20 years ago, it would be worth $661,964.76 today based on a price of $152.88 for NVDA at the time of writing.
<h3>NVIDIA's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751405494_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

Here's How Much You Would Have Made Owning NVIDIA Stock In The Last 20 Years

Stock Split

REVB

Revelation Biosciences Reveals 1-For-3 Reverse Stock Split Effective July 7, 2025

On Friday, June&nbsp;27, the Federal Reserve released the results of its 2025 Comprehensive Capital Analysis and Review ("CCAR") stress test process. Goldman Sachs expects the firm's Stress Capital Buffer ("SCB") requirement will be 3.4%, resulting in a Standardized Common Equity Tier 1 ("CET1") ratio requirement of 10.9%, effective October 1.
The Federal Reserve will provide the firm's final SCB requirement by August 31. These results and effective date may be subject to further changes pending the finalization of the Federal Reserve's outstanding proposal on SCB averaging.
In addition, the Federal Reserve disclosed that the firm's current SCB, from the CCAR 2024 test, has been reduced by 10&nbsp;basis points to 6.1%. This results in a current CET1 ratio requirement of 13.6%, effective immediately.

Goldman Sachs Expects 2025 Stress Capital Buffer Of 3.4% And Common Equity Tier 1 Requirement Of 10.9% Starting October; Federal Reserve Lowers Goldman Sachs' Current SCB To 6.1%, Setting CET1 Requirement At 13.6%, Effective Immediately

The firm's capital plan includes a 33% increase in the common stock dividend from $3.00 to $4.00 per share beginning July 1, 2025, subject to approval by the firm's Board of Directors at the customary third quarter meeting. This increase is a continuation of the firm's plan to pay shareholders a sustainable and growing dividend.

Dividends

Goldman Sachs Group Intends To Increase Its Common Stock Dividend From $3.00 To $4.00 Per Share Beginning July 1, 2025

Centene Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares are tumbling in Tuesday&#8217;s after-hours session after the health care company withdrew its <a href="https://www.benzinga.com/pressreleases/25/07/n46208548/centene-corporation-withdraws-2025-guidance">guidance for 2025</a>.
What Happened: Centene withdrew its previous 2025 earnings guidance and all underlying guidance elements based on the company&#8217;s preliminary interpretation of marketplace data from the independent actuarial firm Wakely.
The company said that overall market growth in 22 of the company&#8217;s 29 marketplace states is lower than previously expected and implied aggregate market morbidity in those states is significantly higher than the company&#8217;s assumptions for risk adjustment revenue transfer.
Centene&#8217;s preliminary analysis of the days resulted in an estimated reduction of its previous full-year net risk adjustment revenue transfer&nbsp;expectations of approximately $1.8 billion, representing an adjusted earnings impact of approximately $2.75 per share. 
&#8220;The Company does not have information or estimates for its remaining seven Marketplace states, but anticipates, due to the morbidity trends observed in the 22 states, an additional reduction to its net risk adjustment revenue transfer expectation with a corresponding adjusted diluted EPS impact,&#8221; the company said.
Centene noted that it began the process of refiling 2026 marketplace rates to reflect a higher projected baseline of marketplace morbidity than previously expected.&nbsp;
Centene said its Medicaid business has experienced a step-up in medical cost trends. As a result, the company expects the Medicaid Health Benefits Ratio in the second quarter to be higher than the&nbsp;first quarter. Centene also said its Medicare Advantage and Medicare Prescription Drug Plan businesses are performing above expectations in the&nbsp;second quarter.
Centene expects to report <a href="https://www.benzinga.com/calendars/earnings">second-quarter results</a> on July 25. The company will provide additional insights at that time. 
CNC Price Action: <a href="http://benzinga.com/quote/CNC">Centene shares</a> were down 21.80% at $44.30 in after-hours Tuesday at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/movers/25/07/46202931/12-health-care-stocks-moving-in-tuesdays-intraday-session">12 Health Care Stocks Moving In Tuesday&#8217;s Intraday Session</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Guidance

Health Care

After-Hours Center

Movers

Centene Withdraws 2025 Guidance, Shares Dive

On June 27, 2025, the Federal Reserve released the results of its 2025 bank stress test, which underscore BNY's resilient business model and strong balance sheet. The Federal Reserve also notified the company that its preliminary Stress Capital Buffer ("SCB") requirement will remain 2.5%, equal to the regulatory floor. This SCB is expected to be effective from October 1, 2025, to September 30, 2026, under the current capital plan rule. Since the introduction of the SCB requirement in 2020, BNY's SCB has consistently remained at the 2.5% floor. The company does not anticipate any impact on its SCB requirement based on the Federal Reserve's notice of proposed rulemaking to reduce the volatility of the SCB requirement issued on April 17, 2025.

BNY's Stress Capital Buffer To Remain At 2.5% Floor Through 2026

Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) has outperformed the market over the past 5 years by 9.35% on an annualized basis producing an average annual return of 23.62%. Currently, Energy Transfer has a market capitalization of $61.33 billion. 
Buying $1000 In ET: If an investor had bought $1000 of ET stock 5 years ago, it would be worth $2,886.55 today based on a price of $17.87 for ET at the time of writing.
<h3>Energy Transfer's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751404523_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Energy Transfer Stock In The Last 5 Years

Riot Platforms, Inc. ("Riot") issues this press release pursuant to Part 3 of Canadian National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and Part 5 of Canadian National Instrument 62-104 – Take-Over Bids and Issuer Bids in respect of Bitfarms Ltd. ("Company").
Riot announces that on July 1, 2025 it sold 2,802,484 common shares (the "Sold Shares") of the Company representing approximately 0.50% of the issued and outstanding Common Shares (the "Common Shares") of the Company (based on the information contained in the Company's management information circular filed on June 9, 2025 (the "Company's Circular").
The Sold Shares were sold through normal course sales on the Nasdaq Stock Market and other open market trades for a weighted average price of approximately US$0.84 per Sold Share (equivalent to approximately C$1.14 per Sold Share based on the daily exchange rate posted by the Bank of Canada on June 30, 2025 (the "Exchange Rate")) at a price range per Sold Share of approximately US$0.82 to US$0.86&nbsp;(equivalent to approximately C$1.12 to C$1.18 based on the Exchange Rate) for an aggregate amount equal to US$2,349,042.09 (equivalent to approximately C$3,204,798.12 based on the Exchange Rate).
Immediately prior to the sales of Common Shares giving rise to the issuance of this press release, Riot beneficially owned 71,110,860 Common Shares, representing approximately 12.79% of the issued and outstanding Common Shares (based on the information contained in the Company's Circular). Following completion of the aforementioned sales, Riot beneficially owned 68,308,376 Common Shares, representing approximately 12.29% of the issued and outstanding Common Shares as at the date hereof (based on the information contained in the Company's Circular).

Asset Sales

BITF

RIOT

Riot Platforms Sells 2,802,484 Bitfarms Shares At An Average Price Of $0.84/Share, For $2.35M, Reducing Stake From 12.79% To 12.29% In Open Market Transactions

The Bank of New York Mellon Expects To Increase Its Quarterly Cash Dividend On Its Common Shares From $0.47 To $0.53 Per Share, Commencing As Early As Q3 Of 2025

Management

Bank of Hawai'i Promotes Bradley "Brad" S. Satenberg To CFO

Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) (&quot;Alpha Cognition&quot; [ACI], or the &quot;Company&quot;), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families. Additionally, a history of mTBI increases the risk of dementia diagnosis later in life.
Data analysis for this study, supported by the US Department of Defense and conducted in collaboration with US Department of Veterans Affairs investigators and the Seattle Institute of Biomedical and Clinical Research, has been concluded, demonstrating that ALPHA-1062 administration following blast induced mTBI, results in a notable reduction in indices of TBI associated neuropathology.
ALPHA-1062 administration reduced the brain levels of three toxic forms of a brain protein Tau. One of these forms (pTau 217) has been suggested to identify TBI patients at greater risk of long-term cognitive decline. It is also one of the earliest emerging biomarkers in Alzheimer&#39;s disease. A second form of toxic Tau (pTau-S202/T205) can be found in very early-stage pathology in the brains of Alzheimer&#39;s patients before the appearance plaques and tangles. The third form (pTau 231) is elevated in early Alzheimer&#39;s disease and TBI. Taken together, reduction of these toxic forms of pTau suggests a potential role for ALPHA-1062 in the treatment of TBI and that this may additionally positively impact the risk of later developing Alzheimer&#39;s disease.
Additional benefits of ALPHA-1062 were observed following blast trauma. High dose ALPHA-1062 reduced the numbers of myeloid cells which play a critical role in neuroinflammation and tissue repair, as well as the number of astrocytes, which regulate neurotransmitters like glutamate and GABA to support neuronal health. These changes are consistent with reduced neuroinflammation following ALPHA-1062 administration. Finally, nerve growth factor receptor expression, which plays an important role in neuronal survival, was increased in an ALPHA-1062 dose-dependent manner. &quot;These outcomes are in agreement with those of an earlier pre-clinical study in a moderate TBI animal model, both studies demonstrated protective effects of ALPHA-1062, providing support for the continued development of ALPHA-1062 for the treatment of traumatic brain injury,&quot; said Denis Kay, ACI&#39;s Chief Scientific Officer.
Alpha Cognition&#39;s next steps in this program will be to complete formulation of ALPHA-1062 for sublingual administration and conduct a bridging pharmacokinetic study vs. ZUNVEYL&reg; (Benzgalantamine) and an existing intranasal formulation of ALPHA-1062.

Biotech

ACOG

Alpha Cognition Reveals Pre-Clinical Data For ALPHA-1062 Use In A Military Relevant Model Of Repetitive Mild Traumatic Brain Injury; Data Provides Additional Evidence Of Benefits Of ALPHA-1062, In The Treatment Of MTBI Resulting From Repetitive Blast Trauma

Boqii Holding  Plans To Cease The Listing Of Its American Depositary Shares On The NYSE American; The Company Will Implement A 1-For-160 Reverse Stock Split Effective on July 11, 2025

American Bitcoin expected to trade on Nasdaq under the ticker symbol "ABTC"
MIAMI and LAS VEGAS, July 1, 2025 /PRNewswire/ -- American Bitcoin Corp. ("American Bitcoin" or the "Company"), a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure backbone, and Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) ("Gryphon"), an innovative venture in the Bitcoin mining space, today announced the filing of an amended registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in connection with their previously announced stock-for-stock merger transaction (the "Transaction").

IPOs

GRYP

American Bitcoin Expected To Trade On Nasdaq Under Ticker Symbol "ABTC" Following Stock-For-Stock Merger With Gryphon Digital Mining

American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) today announced that the Federal Reserve set the company's preliminary Stress Capital Buffer ("SCB") requirement at 2.5 percent, effective October 1, 2025 through September 30, 2026, based on the results of the 2025 Comprehensive Capital Analysis and Review process. This is the minimum SCB requirement under the applicable regulations and is consistent with American Express' previously disclosed SCB in effect through September 30, 2025.

American Express's Preliminary Stress Capital Buffer Set At 2.5%

<h3>Gainers</h3>
<ul>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) shares increased by 7.4% to $1.75 during Tuesday's after-market session. The company's market cap stands at $41.6 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) shares increased by 6.66% to $1.76. The market value of their outstanding shares is at $1.2 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares rose 5.54% to $0.95. The market value of their outstanding shares is at $1.8 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) shares moved upwards by 4.98% to $0.77. The company's market cap stands at $78.9 million. </li>
<li>Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) shares rose 4.95% to $2.12. The market value of their outstanding shares is at $50.7 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock moved upwards by 4.76% to $2.2. The company's market cap stands at $6.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock declined by 14.4% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $11.7 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock declined by 9.35% to $0.29. The market value of their outstanding shares is at $1.8 million. As per the press release, H1 earnings came out today. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock fell 5.67% to $1.5. The company's market cap stands at $50.2 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock declined by 5.56% to $1.19. The company's market cap stands at $14.7 million. </li>
<li>Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) shares decreased by 4.97% to $1.34. The company's market cap stands at $18.9 million. </li>
<li>Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) stock fell 4.95% to $15.18. The market value of their outstanding shares is at $446.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EZGO

HOUR

KXIN

MNRO

NVFY

PRPL

SYPR

TLYS

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) shares moved upwards by 24.0% to $5.99 during Tuesday's after-market session. The market value of their outstanding shares is at $38.9 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 18.7% to $3.11. The company's market cap stands at $4.4 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) stock moved upwards by 8.69% to $0.77. The company's market cap stands at $40.4 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 8.56% to $0.73. The company's market cap stands at $51.4 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares increased by 6.95% to $0.34. The market value of their outstanding shares is at $11.2 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 6.45% to $1.65. The company's market cap stands at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 20.5% to $45.03 during Tuesday's after-market session. The market value of their outstanding shares is at $27.0 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares fell 17.14% to $1.7. The company's market cap stands at $4.1 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock fell 12.79% to $0.3. The company's market cap stands at $6.6 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares decreased by 9.55% to $0.28. The company's market cap stands at $13.3 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 9.29% to $9.48. The company's market cap stands at $250.5 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 8.09% to $0.25. The market value of their outstanding shares is at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

DBVT

GNPX

MBIO

MODD

OGEN

PLUR

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

Press Releases

Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million

Meihua International Medical Technologies Facilitates World's Second* 5G Remote Robot-Assisted Lobectomy

Meihua International Medical Technologies Co., Ltd. to Present at LIVE! with Webull Corporate Connect: Virtual Healthcare Investment Webinar on August 28, 2024

Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results

Meihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement

Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results

Comments

Meihua Intl Medical Techs

Meihua Intl Medical Techs (MHUA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL